HK investor pumps cash to fund China heart cell therapy JV with Cardio3
This article was originally published in Clinica
Executive Summary
Belgian biotech Cardio3 BioSciences has secured a foothold in the much sought-after Chinese market after partnering up with Hong Kong-based investor Medisun International.